Johnson & Johnson JNJ

$266.08 +2.27 (0.86%)

Valuation

Market cap
635,072,512,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
25.13
Forward PE
24.07
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
3,137,105
Avg volume
6,964,168
Day's range
$264.97 – $272.36
Shares out
2,407,310,000
Stochastic %K
76%
Beta
0.21
Analysts
Strong Sell
Price target
$282.24

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

TearsForFear Oct 26, 6:39 PM
$IBRX By locking its database for the BCG-naive trial and eyeing additonal label expansions, the battle for market share Vs $JNJ is really just hitting its stride as both companies push for positioning ahead of wider adoption. Moving into the BCG-naive population is the ultimate prize because that's where the vast majority of early-stage bladder cancer patients land first, bypassing the "unresponsive" stage entirely. Instead of catching patients after standard BCG has already failed them, Anktiva plus BCG could become part of the initial standard of care right out of the gate. That dramatically expands the addressable patient pool and cuts out months or years of trial-and-error treatments. Unlike J&J's TAR-200 localized gemcitabine device system, Anktiva’s mechanism is designed to enhance standard BCG by driving both innate and adaptive immune memory. If urologists can use Anktiva alongside regular BCG with superior durable response rates shifting the mkt preference heavily in its favor.
1 replies
Quantumup Oct 26, 6:18 PM
B | Riley reiterated $CMPS Buy-$22 $STIM $JNJ DFTX LLY GHRS HELP Here's what B | Riley said in its note: https://x.com/Quantumup1/status/2114783664756191649?s=20
0 replies
chursinow62 Oct 26, 6:12 PM
$JNJ thought this would keep its gains on promising news
0 replies
ChessGM Oct 26, 6:08 PM
$ORIC is a buy. $JNJ probably "borrowed" ORICs IP. Great value.
0 replies
notreload_ai Oct 26, 4:57 PM
$ORIC shares declined after $JNJ reported a 75% tumor response rate with JNJ-6143 in heavily pretreated advanced prostate cancer patients. https://notreload.xyz/xy/oric-drops-after-jnj-reports-strong-prostate-cancer-data/
0 replies
SellasgpsCurativeBAT11 Oct 26, 3:00 PM
$AZN $BMY $JNJ $PFE $SLS Time has frozen for me since this E mail hit my Folder. Upcoming Events December 12, 2026 12:00 AM ASH Annual Meeting and Exposition Add to Calendar. Victory Lap. 👇 ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 26, 2:43 PM
$SLS $JNJ $MRK $PFE $BMY Institutional buyers will own 80% of Sellas shares when final BO 10K is Filed. Institutional buyers steady accumulation continues on level 2. ✌️🙏❤️‍🩹
1 replies
Gfywoody Oct 26, 2:31 PM
$JNJ Curious to know when they announce Sellas buyout.
0 replies